中国科学院方面还梳理了目前该院发现的部分侵权行为，共计29项。分别是： 2月11日，中国科学院发布声明：中国科学院是国务院直属事业单位，享有"中国科学院"、"中科院"等名称的专属使用权、商标专用权，以及院标识的著 作权。 中国科学院作为国家科学技术界最高学术机构、国家科学技术思想库、自然科学基础研究与高技术综合研究的国家战略科技力量，院本部不从事任何具体 产品，包括医疗用品、药品和保健品的生产和经营，任何单位或者个人未经该院许可或者授权，在其产品或者服务宣传上使用"中国科学院"、"中科院"等 名称或者中国科学院的标识的行为均属侵犯中国科学院合法权益的违法行为。 中国科学院将保留对相关侵权行为人依法追究全部法律责任的权利，由此造成的一切后果全部由侵权行为人承担。 中国科学院表示，一段时期以来，社会上不断发生一些单位或者个人，通过网络、媒体、宣传单等各种方式，发布盗用中国科学院名称、标识为其产品或 者服务项目的虚假广告宣传，不仅扰乱了正常的市场经济秩序，误导、欺骗了广大消费者，侵犯了他们的合法权益，而且严重侵犯了该院的名称权、名誉 权和知识产权。 10. 石油皂:在报纸宣传中使用"中科院"名称,号称"中科院成功研 ...

Group 1 - The core point of the news is that Zhongxing Mushroom Industry has seen a stock price increase of 5.34%, reaching 15.98 CNY per share, with a trading volume of 1.57 billion CNY and a turnover rate of 2.61%, resulting in a total market capitalization of 6.284 billion CNY [1] - Zhongxing Mushroom Industry, established on November 18, 2005, and listed on June 26, 2015, is primarily engaged in the research, industrial cultivation, and sales of edible mushrooms [1] - The main revenue composition of Zhongxing Mushroom Industry includes: 63.04% from Agaricus bisporus, 35.32% from Enoki mushrooms, 0.89% from Cordyceps, 0.53% from Cordyceps sinensis (ecological breeding), and 0.22% from other sources [1] Group 2 - Hongli Fund's Hongli Consumer Dividend Index A (008928) is among the top ten circulating shareholders of Zhongxing Mushroom Industry, having increased its holdings by 363,100 shares to a total of 3.498 million shares, representing 0.9% of the circulating shares [2] - The fund has achieved a year-to-date return of 1.67% and a one-year return of 10.02%, ranking 4645 out of 5542 and 3851 out of 4256 in its category, respectively [2] - The fund manager, Li Tingting, has a tenure of 4 years and 26 days, with the fund's total asset size at 2.322 billion CNY and a best return of 44.14% during her tenure [2]

为推动更多的北虫草走出国门，为种植户带来收益，沈阳海关所属辽阳海关成立专项服务组，创 新"备案+监管+通关"三位一体机制，将多项出口资质办理时限压缩60%，并举办十余场"云端课堂"，为 企业传授覆盖农药使用、疫病监测和有害物质控制的全链条质控知识。同时，海关精准回应鲜活产 品"抢鲜"所需，开辟农食"绿色通道"，构建"全链条护航"模式。针对海外订单小批量、高频次特点，灵 活运用"优先查验+预约查验"，实现北虫草"即报即检、快速验放"。 小小北虫草，已成为当地致富的宝贝。如今在灯塔市，400余栋虫草大棚铺展开来，从菌种培育、 精深加工到全球贸易，一条完整的产业链已经形成，年产值超千万元。更为可喜的是，产业兴旺直接惠 及农民，带动周边4个村庄300余户增收致富。 在辽阳灯塔市柳条寨镇金康农业合作社的无菌车间里，中央控制系统精密调节着温度、湿度和光 线，立体栽培架上的北虫草如金色细浪般整齐铺展。同时，工人们正将一批两吨重的虫草小心地装箱， 准备发往新加坡。 灯塔市富产的小麦等绿色原料，为北虫草的培育提供了天然材料。北虫草富含虫草素、多糖等活性 成分，可以增强免疫力，而且价格亲民，不仅风靡国内市场，更日益赢得欧美、日韩 ...

Core Insights - The "2025 Fifth National Cordyceps Conference" held in Guiyang, Guizhou, focused on the sustainable and high-quality development of the Cordyceps industry, emphasizing the transition from resource dependence to technology-driven growth [1][3] Industry Development - The conference highlighted the importance of protecting Cordyceps resources, breakthroughs in artificial cultivation technology, deep processing innovations, and the establishment of industry standards [1][4] - Guizhou University has been a pioneer in Cordyceps research since the 1970s, achieving significant breakthroughs in functional analysis and establishing a comprehensive identification system [1][3] Technological Advancements - The university has developed a cultivation technique for Cordyceps with a fungal content of 1.8%, which has received multiple provincial science and technology advancement awards [1][3] - The company Zhongxing Junye has built a leading-scale production line for North Cordyceps, achieving a daily output of 10 tons and overcoming challenges in small bottle cultivation technology [5] Industry Challenges and Solutions - The industry faces challenges such as the scarcity of wild resources and the need for standardization. Proposed actions include establishing product identification standards, advancing deep processing technologies, and enhancing brand building [4][5] - The conference served as a platform for recognizing contributions to technology, ecological protection, and international standard formulation, with awards given to eight organizations [7] Future Directions - The Cordyceps industry is seen as a significant opportunity under the Healthy China strategy, with a focus on exploring new varieties and optimizing existing functional categories to meet diverse health needs [4][5] - The conference aims to facilitate collaboration between academia and industry, promoting the transition from a resource-rich country to a strong industrial nation in Cordyceps [7]

Financial Performance - The company's revenue for 2024 was CNY 1.935 billion, a year-on-year increase of 0.21% [3] - The net profit attributable to shareholders for 2024 was CNY 128 million, a year-on-year decrease of 19.77% [3] - Financial expenses for the years 2022 to 2024 were CNY 57.76 million, CNY 47.86 million, and CNY 46.93 million respectively [3] Debt and Financing - The company's interest-bearing debt has increased to CNY 2.37 billion, with short-term borrowings exceeding CNY 600 million [2] - The asset-liability ratios for 2022, 2023, and 2024 were 48.48%, 43.44%, and 46.39% respectively [3] Market Conditions - The decline in the price of the main product, enoki mushrooms, is attributed to market oversupply, leading to lower sales prices [3] - The company is focusing on its complementary product, Agaricus bisporus, which has seen stable prices due to lower competition [3] Strategic Initiatives - The company is investing in the industrialization of Cordyceps sinensis cultivation, with projects progressing as planned and initial profitability achieved [4][5] - Automation is being introduced in production lines, although the company has not yet implemented robotic harvesting [4] Shareholder Returns - A cash dividend of CNY 3.00 per 10 shares (including tax) is proposed for 2024, following a total cash dividend of CNY 236 million from 2022 to 2023 [6] - The company has completed a share buyback of 18,498,826 shares for a total amount of CNY 143 million (excluding transaction fees) [6]